Foundayo vs Wegovy Pill (2026): 16.6% vs 12.4% Weight Loss, $149 vs $1,349/mo Self-Pay

Oral Wegovy (semaglutide 25mg) produces 16.6% body weight loss over 68 weeks versus Foundayo's (orforglipron) 12.4% over 72 weeks, per the OASIS and ATTAIN-1 trials. Foundayo WAC (list price): $649/month. Self-pay via LillyDirect: $149/month starter dose, $299/month maintenance. Oral Wegovy list price: $1,349/month. Both drop to $25/month with commercial insurance + savings card. Foundayo now shipping through Amazon Pharmacy (same-day delivery), GoodRx, Weight Watchers, Ro, and LillyDirect as of April 2026. Wegovy requires strict empty-stomach dosing (30 minutes before food, with ≤4 oz water). Foundayo can be taken any time with or without food. Both were FDA-approved for chronic weight management: oral Wegovy in December 2025, Foundayo on April 1, 2026.

Quick answer by priority: If maximum weight loss matters most → oral Wegovy (16.6% in OASIS-4). If convenience matters most → Foundayo (no fasting, no water restrictions). If cost matters most → Foundayo ($149/mo starter self-pay vs $1,349/mo Wegovy list). If you want an injection instead → compounded tirzepatide (20.9% loss) via Enhance MD from $99 first month or compounded semaglutide via Enhance MD from $49 first month. For Medicare beneficiaries, both pills are eligible for $50/month coverage under the GLP-1 Bridge program starting July 1, 2026.

This comparison is based on FDA prescribing information, published data from the ATTAIN-1 trial (Foundayo, N=1,401), OASIS-4 trial (oral Wegovy, N=710), Foundayo FDA approval press release (April 1, 2026), and oral Wegovy launch announcement (December 2025). Pricing verified April 2026. For an overview of all oral GLP-1 pills, including how Rybelsus fits and how the pills compare to injectables, see our oral GLP-1 pills compared guide.

How They Work: Two Fundamentally Different Molecules

The most important thing to understand about Foundayo vs oral Wegovy is that they are not the same type of drug. They both activate GLP-1 receptors, but they get there through completely different chemical approaches, and that difference affects everything from how you take the pill to how it behaves in your body.

Oral Wegovy (semaglutide 25 mg) is a peptide, a modified version of the GLP-1 hormone your gut naturally produces after eating. Peptides are chains of amino acids, and they are notoriously difficult to deliver orally because stomach acid and digestive enzymes break them apart before they can be absorbed. Novo Nordisk solved this with a permeation enhancer called SNAC (salcaprozate sodium), which protects the semaglutide molecule and helps it cross the stomach lining into the bloodstream. This is clever pharmaceutical engineering, but it comes with strict requirements: you must take the pill first thing in the morning on an empty stomach with no more than 4 ounces of plain water, then wait 30 minutes before eating, drinking, or taking any other medications.

Foundayo (orforglipron) is a non-peptide small molecule, an entirely synthetic compound that is not based on the natural GLP-1 hormone at all. Instead, it was designed from scratch to bind to and activate the same GLP-1 receptor that semaglutide targets. Because it is a small molecule rather than a fragile peptide chain, it absorbs readily through the gut without being destroyed by stomach acid. This means no fasting requirements, no water restrictions, and no waiting period, you can take it at any time of day, with or without food.

The peptide vs small molecule distinction is not just a chemistry detail, it is the reason these two pills have such different daily experiences for patients. Semaglutide's peptide structure forces the fasting requirement, which can be genuinely disruptive for people with irregular schedules, early medication routines, or who simply find it hard to wait 30 minutes before their morning coffee. Orforglipron's small molecule design eliminates all of that friction.

Clinical Trial Results: Weight Loss Head to Head

Both medications have been through rigorous Phase 3 clinical trial programs. Foundayo's obesity data comes primarily from the ATTAIN-1 trial, published in the New England Journal of Medicine, which enrolled 3,127 adults with obesity but without diabetes. Oral Wegovy's weight loss data comes from the OASIS 4 trial, which evaluated semaglutide 25 mg in a similar population. While no head-to-head trial has directly compared these two pills at their obesity-approved doses, we can draw meaningful comparisons from their respective Phase 3 results.

The numbers tell a clear story: oral Wegovy produces more weight loss than Foundayo across every metric. At the highest doses, adherent patients on oral Wegovy lost an average of 16.6% of body weight compared to 12.4% on Foundayo. One-third of oral Wegovy patients achieved at least 20% weight loss, compared to roughly one in five on Foundayo. This gap is consistent and statistically meaningful.

However, context matters enormously here. Foundayo's 11.2% mean weight loss is still clinically significant, for a 250-pound person, that translates to roughly 28 pounds lost. The FDA approved it because those results are meaningful for reducing obesity-related health risks. And there are reasons the raw percentages do not tell the whole story:

• •Trial duration differed, ATTAIN-1 ran for 72 weeks while OASIS 4 ran for 64 weeks, yet Foundayo still showed lower weight loss despite the longer treatment period. This suggests the efficacy gap is real, not an artifact of study design.
• •Adherence rates matter in real life, oral Wegovy's strict fasting requirements may reduce real-world adherence compared to clinical trial conditions. Foundayo's no-restrictions dosing could mean better real-world compliance, potentially narrowing the effectiveness gap outside of controlled studies.
• •Dose-response was clear, Foundayo showed a dose-dependent pattern in ATTAIN-1: 7.5% at 6 mg, 8.4% at 12 mg, and 11.2% at 36 mg. The approved range goes up to 17.2 mg for maintenance, and providers have flexibility to optimize dosing for each patient.
• •Cardiometabolic improvements, both medications showed improvements in waist circumference, blood pressure, triglycerides, and non-HDL cholesterol beyond weight loss alone. Foundayo specifically showed significant improvements in systolic blood pressure and triglyceride levels in the ATTAIN-1 data.

Dosing Schedules: Getting Started and Staying On Track

Both Foundayo and oral Wegovy use a gradual dose-escalation approach, you start low and increase over time to minimize gastrointestinal side effects. But the schedules differ significantly in their complexity, number of dose steps, and daily experience.

Foundayo dosing schedule:

Oral Wegovy dosing schedule:

Foundayo has a more gradual titration with six possible dose levels, while oral Wegovy moves through four doses more quickly to reach its 25 mg maintenance. The Foundayo schedule allows providers more flexibility to find the right dose, some patients may do well at 9 mg without needing to escalate further, while others may need the full 17.2 mg. Oral Wegovy, by contrast, has a single target maintenance dose of 25 mg that most patients are expected to reach.

The daily experience of taking each pill is where the real divergence shows up:

• •Foundayo: Take one pill at any time of day. With or without food. With any beverage. Before, during, or after meals. Alongside other medications. There are essentially no administration restrictions, it works like most daily pills people are already used to taking.
• •Oral Wegovy: Wake up. Take the pill on a completely empty stomach with a small sip of water (4 oz maximum, plain water only). Swallow the tablet whole, do not chew, crush, or split it. Set a timer for 30 minutes. Do not eat, drink anything else, or take any other oral medications during that waiting period. After 30 minutes, resume your normal routine.

For some people, the Wegovy routine is a minor inconvenience they barely notice. For others, particularly those with demanding morning schedules, shift workers, people who take multiple morning medications, or those who need coffee first thing, it is a genuine daily burden. Clinical data on oral semaglutide (from the Rybelsus program) shows that adherence to fasting requirements meaningfully affects absorption and therefore efficacy. Patients who do not follow the fasting protocol closely may not absorb the full dose, reducing effectiveness.

Side Effects: What the Clinical Data Shows

Both Foundayo and oral Wegovy cause gastrointestinal side effects, this is the hallmark of GLP-1 receptor agonists regardless of whether they are pills or injections. The GI effects are most common during dose escalation and tend to improve over time as your body adjusts. However, the specific rates and patterns differ between the two medications.

The side effect profiles share the same GI-heavy pattern common to all GLP-1 drugs, but there are notable differences. Oral Wegovy tends to produce higher rates of nausea and diarrhea, while Foundayo has a somewhat broader range of GI complaints including heartburn, belching, gas, and indigestion that are less prominently reported with oral semaglutide. Foundayo also lists hair loss as a common side effect, something that has been reported anecdotally with other GLP-1 drugs but appears more frequently in the orforglipron data.

The discontinuation rates tell an important story. In ATTAIN-1, 10.3% of patients on the highest Foundayo dose (36 mg) discontinued treatment due to adverse events, compared to 2.7% on placebo. For oral Wegovy, the discontinuation rate due to adverse events has generally been lower in clinical trials. This suggests Foundayo may be slightly less tolerable at the highest doses, though both medications are within the range considered acceptable for GLP-1 drugs.

• •Both medications carry a boxed warning about the potential risk of thyroid C-cell tumors, based on animal studies. It is not known whether this risk applies to humans. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• •Pancreatitis risk exists with both medications. Patients should report severe abdominal pain that does not resolve, especially if it radiates to the back.
• •Gallbladder events including gallstones and cholecystitis have been reported with both GLP-1 medications at rates higher than placebo.
• •Hypoglycemia is uncommon with either medication when used alone for weight management, but risk increases if combined with insulin or sulfonylureas for diabetes.

Pricing Comparison: April 2026

Pricing is one area where Foundayo has a clear, measurable advantage. Eli Lilly priced Foundayo significantly below oral Wegovy at the list price level, a deliberate competitive strategy to drive adoption of Lilly's newer product against Novo Nordisk's established semaglutide franchise.

At the self-pay and insured patient level, Lilly has matched Novo Nordisk's pricing almost exactly, $149 for starter doses, $299 for maintenance, $25 with commercial insurance. The real difference is in the list price: Foundayo's $649 WAC is less than half of oral Wegovy's $1,349. This matters for several reasons:

• •Insurance negotiations, a lower list price gives pharmacy benefit managers (PBMs) and insurers more room to negotiate favorable formulary placement for Foundayo. Over time, this could mean Foundayo lands on more insurance formularies as a preferred GLP-1 pill.
• •Uninsured and underinsured patients, while the savings card programs equalize prices for many, patients who fall through the cracks (no insurance, exhausted savings card benefits, or high-deductible plans) will face significantly lower out-of-pocket costs with Foundayo.
• •Medicare pricing, under the Inflation Reduction Act's negotiation provisions and the upcoming Medicare GLP-1 Bridge program, a lower list price could translate to lower Part D costs for Medicare beneficiaries.
• •Long-term pricing trends, Novo Nordisk has already announced list price cuts of approximately 50% for Wegovy effective January 2027, which would bring it closer to Foundayo's current list price. The pricing war between these two companies benefits patients.

Foundayo distribution confirmed April 12, 2026: LillyDirect (direct-to-patient, shipped since April 6), Amazon Pharmacy (confirmed same-day delivery in eligible zip codes), GoodRx (discount pricing at retail pharmacies), Weight Watchers (formal Foundayo program partner, members get guided GLP-1 support through the WW clinical program), and Ro (telehealth prescriptions via LillyDirect fulfillment). Self-pay through any channel: $149/month starter dose, $299/month maintenance dose. With commercial insurance + Lilly savings card: as low as $25/month. For alternative GLP-1 routes at even lower price points, compounded injectable options start at $146/month compounded semaglutide via Yucca Health or $149/month microdose tirzepatide via Gala. Oral Wegovy has been broadly available at retail pharmacies since January 2026.

Use our cost calculator to model your specific out-of-pocket cost for either medication based on your insurance status, location, and available savings programs.

Launch Trajectory: What the IQVIA Data Shows, and Why It Understates Foundayo

Foundayo's first three weeks of prescription data are well-documented via IQVIA; the weeks after that are where it gets murky, and where most coverage quietly reports analyst projections as if they were facts. Here is what is actually verified (Week 1 per BioSpace, Week 2 per pharmaphorum) versus what is an estimate:

Week 1: Foundayo recorded 1,390 prescriptions over a 2-day capture window (shipped Thursday April 9, weekly cutoff Saturday April 11). Oral Wegovy hit 3,071 in its launch week with 5 days of capture (launched Monday January 5). Normalized for capture days, the two pills entered the market at broadly comparable velocity, both substantially outpacing the GLP-1 injectables that came before them (injected Zepbound 1,100 launch-week Rx; injected Wegovy 768).

Week 2: with both pills having a full 7-day window for the first time, oral Wegovy hit 18,410 prescriptions while Foundayo hit 3,707. Oral Wegovy outpaced Foundayo by roughly 5x in their respective Week 2 windows. The earlier read that Foundayo was "pacing ahead" of Wegovy pill's trajectory turned out to be premature, Wegovy pill's Week 2 surge from 3,071 to 18,410 (a 6.0x multiplier) far outran Foundayo's 1,390 to 3,707 (a 2.7x multiplier).

Week 3: Foundayo reached 5,612 prescriptions, a +51% week-over-week gain, down from the +167% surge seen in Week 2. This deceleration is a normal launch pattern: an early-adopter surge in Week 2, followed by a step-down in velocity as the first wave clears. The relevant industry benchmark is IQVIA's 90,000-Rx-by-Week-12 threshold, the level typically cited as a marker of a successful drug launch. At 5,612 total Rx through Week 3, Foundayo needs to sustain roughly 7,600 additional Rx per week on average over the next nine weeks to reach that benchmark. Distribution was still ramping: Amazon Pharmacy same-day delivery launched mid-April, and Weight Watchers' formal Foundayo program integration was announced in late April, both channels were not fully active during the first three weeks.

Coverage timeline, the part that actually changes your copay: The real Foundayo catalyst is insurance, and the dates are staggered and easy to misread. Per the CVS Caremark announcement of May 28, 2026, CVS removed the "new-to-market block" on Foundayo effective June 1, 2026, making it coverable (not auto-added) on CVS Caremark's standard commercial formulary template, roughly 25–30 million covered lives. The same announcement restores Zepbound as a co-preferred option effective October 1, 2026, so a patient trying to fill Zepbound on CVS Caremark between June and September may still be blocked unless their specific plan already covers it. Important nuance: this is a CVS-Caremark-specific move, not an industry-wide shift, Express Scripts and OptumRx set their own formularies. And "where approved for coverage by plans" means a self-insured employer can still opt out of GLP-1 coverage entirely, so "CVS covers it" does not guarantee *your* plan does. Separately, the Medicare GLP-1 Bridge launches July 1, 2026, covering Foundayo at $50/month for qualifying Part D beneficiaries, the Bridge is the weight-management pathway for patients who do NOT have a Part D-eligible diagnosis like type 2 diabetes or sleep apnea (those route through standard Part D). See our Bridge enrollment guide for the three-tier BMI rule.

What this means for patients: demand momentum is no longer a tie. Oral Wegovy is the volume leader by a wide margin and is clearly easier to access at parity pricing. That said, raw prescription volume is not the same as fit. The decision still comes down to: fasting tolerance (Wegovy pill requires a 30-minute pre-dose fasting window; Foundayo does not), efficacy expectation (Wegovy 16.6% vs Foundayo 12.4% body weight loss in head-to-head trial conditions), and your specific out-of-pocket cost, which depends entirely on whether you have insurance, which plan, and which pharmacy. For a typical uninsured patient comparing prices today, both pills are accessible at $149/mo. For an insured patient, oral Wegovy via the savings card is materially cheaper at $25/mo until the Medicare GLP-1 Bridge launches July 1 2026 at $50/mo for both.

ACHIEVE-3: The Foundayo vs Oral-Semaglutide Head-to-Head (and What "73.6%" Really Means)

The single most-misreported Foundayo number is the "73.6% greater weight loss" headline from ACHIEVE-300202-3/abstract), the 52-week, 1,698-patient head-to-head Phase 3 trial pitting Foundayo against oral semaglutide (the same molecule inside the Wegovy pill) in adults with type 2 diabetes. That 73.6% is a relative difference, not the weight you would lose. Here is the honest breakdown.

One labeling wrinkle worth knowing: the ACHIEVE-3 Lancet paper00202-3/abstract) calls the top dose "orforglipron 36 mg," while Lilly's commercial materials call the same arm Foundayo 17.2 mg, different names, identical results. ACHIEVE-3 was presented at the ADA 86th Scientific Sessions on June 8, 2026 alongside ACHIEVE-2 and ACHIEVE-5. Bottom line for a shopper: head-to-head against the pill inside oral Wegovy, Foundayo came out ahead on both blood sugar and weight in diabetes patients, but the real-world weight numbers are single-digit percentages, not the eye-catching relative figure.

Cardiovascular and Metabolic Benefits Beyond Weight Loss

Weight loss is the primary endpoint, but both GLP-1 pills offer health benefits beyond the number on the scale. However, the depth of clinical evidence differs significantly between the two.

Oral Wegovy carries an FDA-approved indication for cardiovascular risk reduction in adults with obesity and established heart disease. This is based on the landmark SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events with injectable semaglutide 2.4 mg. While the SELECT trial used the injectable formulation, the FDA extended the cardiovascular indication to oral Wegovy based on the shared active ingredient. This cardiovascular label is a significant clinical and insurance advantage, it gives providers another basis for prescribing and can unlock coverage through cardiovascular benefit pathways even when weight loss coverage is denied.

Foundayo does not have a cardiovascular indication. It was approved specifically for chronic weight management. The ATTAIN-1 trial did show improvements in cardiometabolic markers, including reductions in systolic blood pressure, triglycerides, and non-HDL cholesterol, but these were secondary endpoints, not the basis for a separate FDA indication. Eli Lilly has ongoing cardiovascular outcomes trials for orforglipron, but results are not yet available.

For patients with established cardiovascular disease who are choosing between these two pills, oral Wegovy's cardiovascular indication is a meaningful differentiator. It provides both clinical evidence of heart benefit and a practical insurance coverage pathway that Foundayo cannot currently match.

Both medications showed improvements in prediabetes markers. In OASIS 4, more than 70% of oral Wegovy patients with prediabetes at baseline had normalized blood glucose by the end of the trial. Foundayo's ATTAIN-1 data also showed glucose improvements, though the drug is not yet approved for diabetes treatment (Eli Lilly plans to submit for a Type 2 diabetes indication in 2026).

Switching: What If You're Already on a GLP-1?

Many people considering Foundayo or oral Wegovy are not starting GLP-1 treatment from scratch, they may be on injectable Wegovy or Zepbound and want to switch to a pill, or they may be on one oral GLP-1 and curious about the other. The switching landscape is new territory, but early data and clinical guidance are emerging.

Switching from injectable GLP-1 to Foundayo: Eli Lilly specifically studied this scenario. The ATTAIN-MAINTAIN trial showed that patients who switched from injectable incretins (including Wegovy) to orforglipron maintained all but 0.9 kg of their previously achieved weight loss on average. This is encouraging data for people who want to move from injections to pills without losing their progress.

Switching from injectable Wegovy to oral Wegovy: Since both are semaglutide, the transition involves moving from weekly injections to daily pills. However, oral bioavailability differs from injectable, so patients need to start at the 1.5 mg oral dose and titrate up to 25 mg regardless of their prior injectable dose.

Switching between Foundayo and oral Wegovy: There is limited published data on directly switching between these two pills. Because they are different molecules (orforglipron vs semaglutide), there is no direct dose equivalence. A patient switching from one to the other would likely need to start the new medication at or near the starting dose and titrate up, guided by their provider's judgment. This is an area where clinical experience will develop rapidly as both medications see wider use.

Which Pill Should You Choose?

The right choice depends on what matters most to you. Neither pill is universally better, they have distinct strengths that align with different patient priorities. Here is a framework for thinking through the decision:

Choose Foundayo if:

• •Convenience is your top priority, Foundayo's no-restrictions dosing (any time, with or without food) eliminates the daily friction that comes with oral Wegovy's fasting requirements. If you know you will struggle with the 30-minute fasting window, Foundayo removes that barrier entirely.
• •You are a shift worker or have an irregular schedule, the ability to take Foundayo at any time of day, regardless of meals, makes it far more practical for people who do not have a consistent morning routine.
• •You are price-sensitive and paying out of pocket, while self-pay prices are currently matched, Foundayo's significantly lower list price ($649 vs $1,349) means lower costs for uninsured patients and better long-term positioning as a budget-friendly option.
• •You prefer the Eli Lilly ecosystem, if you are already using LillyDirect or have Lilly savings cards, Foundayo integrates seamlessly with Lilly's existing direct-to-patient infrastructure.
• •You want to switch from injectable Zepbound without changing manufacturers, Foundayo gives Lilly patients an oral option within the same portfolio, with clinical data (ATTAIN-MAINTAIN) supporting the switch from injectables.
• •Moderate weight loss meets your goals, if you are targeting 10-12% body weight reduction rather than 15-20%, Foundayo's efficacy profile may be sufficient, and the convenience advantage tips the balance.

Choose oral Wegovy if:

• •Maximum weight loss is your goal, oral Wegovy's 16.6% adherent weight loss significantly exceeds Foundayo's 12.4%. If every percentage point matters to you, Wegovy delivers more.
• •You have cardiovascular disease or risk factors, oral Wegovy's FDA-approved cardiovascular indication, backed by the SELECT trial, provides both clinical benefit and an insurance coverage pathway that Foundayo cannot offer.
• •You can reliably follow the fasting protocol, if you already take Rybelsus or have no issue with the morning empty-stomach routine, the dosing restriction may not feel like a burden, and you get the efficacy advantage.
• •You want the most clinically established GLP-1 molecule, semaglutide has years of real-world data, multiple large-scale trials (STEP, OASIS, SELECT), and a track record that orforglipron simply has not had time to build yet.
• •Your insurance covers Wegovy but not Foundayo, formulary placement will evolve, but oral Wegovy had a head start. Check your plan's current formulary before deciding.
• •You are on Medicare and eligible for the GLP-1 Bridge, both oral Wegovy and Foundayo are confirmed eligible under the Medicare GLP-1 Bridge program at $50/month starting July 1, 2026. At parity pricing, the choice between them on Medicare comes down to the same factors as cash-pay: fasting tolerance and efficacy priority.

Not sure which factors matter most for your situation? Our match quiz accounts for your schedule, insurance, budget, and medication preferences to recommend the best GLP-1 option, including both oral and injectable formulations.

How Both Pills Compare to Injectable GLP-1s

An important question many patients are asking: should I switch from my weekly injection to one of these pills? The answer depends on your current results and your priorities.

Injectable GLP-1s still produce the highest weight loss numbers, particularly Zepbound (tirzepatide) with its dual GIP/GLP-1 mechanism. If you are achieving excellent results on an injectable and tolerating it well, there is no compelling reason to switch to a pill. But if needle aversion, injection fatigue, or convenience is pushing you toward an oral option, both pills offer meaningful weight loss in a more patient-friendly format.

The oral formulations also have a potential role as a stepping stone, patients can start with the convenience of a daily pill and, if they want more aggressive weight loss, transition to an injectable later. Or conversely, patients who have achieved their weight loss goals on an injectable can step down to a maintenance pill, as the ATTAIN-MAINTAIN data suggests is viable with Foundayo.

Frequently Asked Questions

Is Foundayo the same as Wegovy in pill form?

No. Foundayo (orforglipron) and oral Wegovy (semaglutide) are completely different molecules made by different companies. They both activate GLP-1 receptors, but orforglipron is a synthetic small molecule while semaglutide is a modified peptide hormone. Think of them as two different cars that both run on the same road, they get you to a similar destination through different engineering.

Can I take Foundayo with food?

Yes. Foundayo can be taken at any time of day, with or without food, and with any beverage. There are no fasting requirements or water restrictions. This is one of its primary advantages over oral Wegovy, which must be taken on an empty stomach.

Which pill causes fewer side effects?

Both cause similar types of GI side effects (nausea, diarrhea, vomiting, constipation). Oral Wegovy may have slightly higher nausea rates, while Foundayo has a broader range of GI complaints including heartburn and belching. Foundayo's discontinuation rate due to side effects (10.3% at the highest dose) was somewhat higher than oral Wegovy's. Neither is clearly milder, individual tolerance varies significantly.

Will my insurance cover Foundayo?

Updated June 12, 2026: CVS Caremark added Foundayo to its standard commercial formulary effective June 1, 2026, covering approximately 25–30 million Americans with commercial insurance. Express Scripts and OptumRx formulary decisions are pending as of June 2026. With CVS coverage now active, the Lilly savings card brings eligible CVS-plan members to as low as $25/month. Self-pay through LillyDirect remains $149/month. Individual employer plans adopt PBM formulary updates on their own renewal timelines, check with your insurer for your specific effective date.

Can I switch from oral Wegovy to Foundayo?

Potentially, but only with your prescriber's guidance. Since these are different molecules, there is no direct dose conversion. You would likely need to start Foundayo at or near the starting dose and titrate up. Discuss with your provider whether a switch makes sense based on your current results, side effect experience, and treatment goals.

Is Foundayo approved for diabetes?

Not yet. Foundayo is currently FDA-approved only for chronic weight management. Eli Lilly has announced plans to submit orforglipron for a Type 2 diabetes indication in 2026, but that approval has not yet occurred. If you need a GLP-1 for diabetes, your current options include Ozempic, Rybelsus, Mounjaro, and others, see our beginner's guide for the full list.

What about GLP-1 medications for dogs or other pets?

No GLP-1 medication is currently FDA-approved for dogs. Slentrol (dirlotapide), the only dog weight loss drug ever approved, was voluntarily discontinued by Pfizer Animal Health in 2013. The closest pipeline candidates are Okava's OKV-119 sustained-release implant and Akston Biosciences' AKS-562c weekly injection, both currently in cat trials with dogs planned next. Realistic canine FDA approval timeline: 2028-2029 at the earliest. For the full status, see our Ozempic for Dogs status page and the Okava OKV-119 + Akston AKS-562c tracker. Until pet GLP-1s arrive, the only proven method for canine weight loss is food, portions, and exercise.

Our Bottom Line

The arrival of two competing GLP-1 pills is a genuine milestone for patients. For the first time, you have a real choice in oral GLP-1 treatment, and the two options are meaningfully different rather than interchangeable.

Oral Wegovy is the efficacy leader. It produces more weight loss (16.6% vs 12.4% in adherent patients), has the cardiovascular indication backed by the SELECT trial, and benefits from semaglutide's extensive real-world track record. If your primary goal is maximum weight loss and you can handle the fasting requirements, oral Wegovy delivers better numbers.

Foundayo is the convenience and value leader. Its no-restrictions dosing, any time of day, with or without food, is a genuine practical advantage for daily adherence. Its lower list price positions it well for patients paying out of pocket and for long-term insurance negotiations. And its ATTAIN-MAINTAIN data showing successful transitions from injectables gives it a unique role in the treatment pathway.

The competition between Eli Lilly and Novo Nordisk is already driving prices down and expanding access, and that benefits every patient regardless of which pill they choose. Expect insurance formularies to evolve rapidly as both companies negotiate placement, and expect real-world head-to-head data to emerge over the coming months as providers gain experience with both medications.

If you are new to GLP-1 treatment, start with our ranked list of telehealth providers to find a platform that prescribes the medication you are interested in. Take the match quiz for a personalized recommendation based on your insurance, budget, and preferences. And use the cost calculator to model what either pill would actually cost you before committing.